UCMYM802 / UTC Therap - LARVOL DELTA

Safety and preliminary efficacy of a novel armored mesothelin-targeted CAR-T therapy in advanced solid tumors. (ASCO 2026) - P1 | "UCMYM802 demonstrated a manageable safety profile consistent with expected CAR-T-related toxicities, primarily CRS. Preliminary anti-tumor activity was observed in heavily pretreated patients with MSLN-positive advanced solid tumors, with encouraging signals in gynecologic or peritoneal origin adenocarcinoma and biliary tract cancers. The recommended dose for expansion is 1×10^9 CAR-T cells."

CAR T-Cell Therapy • Clinical • First-in-human • IO biomarker • Metastases • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Hypotension • Lung Cancer • Mesothelioma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • IFNG • MSLN

Trio of Phase I Studies Investigates Mesothelin-Directed CAR T-Cell Therapies. (PubMed, Cancer Discov) - "At the American Association for Cancer Research Annual Meeting, researchers presented data from three separate phase I studies investigating distinct mesothelin-targeted chimeric antigen receptor T-cell therapies: SynKIR-110, UCMYM802, and M28z1XXPD1DNR."

Journal • P1 data • Oncology • MSLN

Safety and preliminary efficacy of a novel LACO-Stim armored mesothelin-targeted CART therapy in advanced solid tumors (AACR 2026) - "UCMYM802 demonstrated a manageable safety profile consistent with expected CAR-T-related toxicities, primarily CRS. Preliminary anti-tumor activity was observed in heavily pretreated patients with MSLN-positive advanced solid tumors, with encouraging signals in gynecologic or peritoneal origin adenocarcinoma and biliary tract cancers. The recommended dose for expansion is 1×10^9 CAR-T cells."

CAR T-Cell Therapy • Clinical • First-in-human • IO biomarker • Metastases • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Lung Cancer • Mesothelioma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • IFNG • MSLN

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: UTC Therapeutics Inc.

New P1 trial • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Mesothelioma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor